South Korea Antiepileptic Drugs Market Size Analysis, Growth Trends & Forecast to 2034

South Korea Antiepileptic Drugs Market Overview 

The South Korea antiepileptic drugs market is projected to expand from USD 0.43 billion in 2026 to USD 0.63 billion by 2034, registering a CAGR of 5.0% during 2026–2034. The South Korea antiepileptic drugs market is propelled by the constant need for the management of epilepsy, the need for seizure control treatment, and the availability of generics and innovative treatments. The South Korea antiepileptic drugs market is made up of traditional antiseizure drugs, such as carbamazepine and levetiracetam, in addition to innovative treatments aimed at meeting the needs of patients who have failed to benefit from traditional treatments. Domestic pharmaceutical companies contribute to the market through the production of generics, while SK Biopharmaceuticals provides an innovative edge to South Korea in terms of epilepsy drugs through cenobamate. Growth in the market will be driven by the affordability of treatment, reimbursement strategies, drug tolerance, and doctors’ preference for customized treatments depending on the type of seizures. Competition will be influenced by price and availability of generics in traditional drug categories.

South Korea Antiepileptic Drugs Market Growth Drivers

Growing need for Long-Term Epilepsy Management

Epilepsy is known to require a long-term pharmacological treatment regimen to control seizures and minimize the probability of seizure relapse, making the continuous demand for antiepileptics in South Korea necessary. The growing aging population and increasing prevalence of neurological conditions related to strokes and other brain diseases are additional factors that contribute to the necessity of managing epilepsy. According to a nationwide study conducted in South Korea and published in Seizure in July 2023, 82,390 new cases of epilepsy were followed, and approximately 8.8% of patients had reached the state of possible drug-resistant epilepsy after seven years. In a nationwide cohort study conducted across South Korea and published in Heliyon on March 7, 2024, the authors assessed 6,746 patients who started add-on antiepileptic treatment from 2016 to 2020. It was observed that 65.5% continued to be on their initial add-on drug regimen during the entire follow-up period of one year, on average for about 307 days. The continuous need for therapy reflects sustained demand for existing medications like levetiracetam and carbamazepine, as well as new therapies for those patients needing more effective or tolerable treatments.

Demand for newer antiseizure therapies

In South Korea, there is a demand for innovative treatment options since people with epilepsy need better seizure control due to inadequate management with conventional antiepileptic agents. Despite the significance of the current treatment drugs for epilepsy, there still exist drug-resistant cases that require alternative treatment options with better effectiveness levels and tolerable adverse effects. For instance, in November of 2025, South Korea's Ministry of Food and Drug Safety approved Cenobamate (Xcopri). This medication, produced by SK Biopharmaceuticals and distributed locally by Dong-A ST, can be used for the management of partial-onset seizures in adult epilepsy cases that are difficult to manage with current medications. Approval of this treatment came at a time when some of the patients in Korea had accessed this medication from abroad.

South Korea Antiepileptic Drug Market Restraint

Treatment Tolerability and Medication-Management Challenges

Poor tolerability and medication management issues may limit the South Korean market for antiepileptic drugs, considering that long-term treatment may involve such side effects as somnolence, dizziness, cognitive dysfunction, and mood changes. In addition, the possibility of drug interactions, complex dosing schedules, and other related issues can negatively affect medication adherence and cause discontinuation or switching of treatment. For patients needing several types of medicines, there will be even more difficulty in maintaining a regular treatment regimen, while healthcare providers should achieve a proper balance between seizure control, adverse effect concerns, and the personal needs of every patient. According to the results of the national South Korean cohort study published in Heliyon in March 2024, which involved 6,746 patients initiating an add-on antiepileptic treatment regimen, 41.0% of them switched from their initial add-on medication within 12 months. This situation may affect continuity of care and require closer clinical observations and follow-up, thus limiting further use of individual drugs.

South Korea Antiepileptic Drug Market Opportunities

Expansion of Innovative Epilepsy Treatments 

The emergence of innovative antiepileptic drugs (AEDs), such as novel-generation anti-seizure medicines, target AEDs, and novel safety and tolerability antiepileptic drugs, offers several prospects for the expansion of South Korea's antiepileptic drugs market. The increasing requirement for improved seizure management, especially in the population suffering from drug-resistant epilepsy, leads to enhanced clinical trials by pharmaceutical companies to bring a novel product to the market. For example, in November 2025, South Korea's Ministry of Food and Drug Safety (MFDS) approved XCOPRI (cenobamate), which is being developed by SK Biopharmaceuticals Company as an addition to the treatment for partial-onset seizures in adults. Moreover, in August 2026, SK Biopharmaceuticals Company announced that it entered into an agreement for the in-licensing of Opakalim, an investigational Kv7 potassium channel activator in Phase 2/3 clinical development for focal-onset seizures.

International Commercialization of Korean-Developed Medicines

There is a large potential for future growth of South Korea's antiepileptic drug market from the international commercialization of the locally manufactured antiepileptic drugs. It would be possible for the South Korean pharmaceutical companies to take advantage of the rising global demand for state-of-the-art products used in seizure management by acquiring regulatory clearance, reaching licensing agreements and partnerships with other foreign firms based in North America, Europe, and Asia-Pacific. The recognition of the revolutionary Korean antiepileptic drugs in the global market could generate revenues through exports, licensing charges, and royalties to help improve the competitiveness of local pharmaceutical producers.

South Korea Antiepileptic Drugs Market Scope

South Korea Antiepileptic Drugs Market Report Segmentation Analysis

The Sodium Channel Modulators Segment Is Expected to Dominate the South Korea Antiepileptic Drugs Market During the Forecast Period

The sodium channel modulators are anticipated to hold a prominent share of South Korea’s antiepileptic drugs market because of their established utility in controlling seizures through regulation of the excess electrical activity in the brain. The drugs find extensive application in treating focal-onset seizures and some generalized types of seizures due to their proven clinical efficacy, wide physician acceptance, and use in the treatment regimen of epilepsy. The continuous need for seizure control, presence of multiple therapies, and established prescribing trends are expected to fuel the demand for the segment over the forecast period. 

Oral Segment Is Expected to Dominate the South Korea Antiepileptic Drugs Market During the Forecast Period

Oral antiepileptics will be responsible for the biggest share in terms of the market, as they are widely prescribed for epilepsy as a means of therapy, are easy to use, and are suitable for long-term treatment in an ambulatory setting. Epilepsy requires constant medication to prevent attacks; thus, oral antiepileptic drugs in the form of tablets, capsules, and mouth solutions can be administered as an option for continuous treatment. Their convenience, accessibility in a wide range of drug types, dosage regulation, and suitability for ambulatory treatment contribute to their popularity in treating adult and pediatric patients. Injectable drugs, on the other hand, are used mostly for emergency treatment and in hospital settings. An epidemiological analysis of the prescription of 18 oral antiseizure drugs for epilepsy conducted by researchers from South Korea has been published in the Journal of Clinical Neurology in 2022.

Tablets and Capsules Segment Is Expected to Dominate the South Korea Antiepileptic Drugs Market During the Forecast Period

The segment of tablets and capsules is likely to hold the largest share in the South Korean antiepileptic drug market owing to the preference for solid oral dosage forms for regular and extended treatment of epilepsy. Solid oral dosage forms provide advantages in terms of ease of administration, precise dosage, easy storage, and suitability for prolonged outpatient treatment. The presence of several antiseizure drug products in the form of tablets and capsules, together with well-established prescribing practices and wide distribution via hospitals and retail pharmacies, ensures high popularity of this segment. Moreover, the availability of both branded and generic products increases access to treatment and facilitates medication adherence.

The Hospital Pharmacies Segment Is Expected to Dominate the South Korea Antiepileptic Drugs Market During the Forecast Period

Hospital pharmacies will be considered key players in the antiepileptic drugs market in South Korea due to the role played by hospitals in the diagnosis and management of seizures among people. Many epilepsy and neurology clinics will be involved in the management of patients who require extensive clinical evaluations as well as drug monitoring, thus generating more demand for the use of antiepileptic drugs via this distribution channel. In addition, the availability of trained health care professionals and other diagnostic tools increases the popularity of this channel for antiepileptic drugs. Additionally, patients who have just been diagnosed with seizures, drug-resistant seizures, or require complex treatment will seek hospital-based health care.

The following segments are part of an in-depth analysis of the South Korea Antiepileptic Drugs Market:

South Korea Antiepileptic Drugs Market Competition Landscape Analysis

Competition exists between local antiepileptic producers in South Korea and foreign companies that produce antiepileptic drugs. Competitive positioning depends on the product's efficacy, safety, cost, reimbursement coverage, brand strength, and distribution capacity. The local companies competing with foreign firms in the antiepileptic drug market include SK Biopharmaceuticals, Dong-A ST, Chong Kun Dang Pharmaceutical, Daewoong Pharmaceutical, and Hanmi Pharmaceutical. Competing foreign companies in the antiepileptic drug market include UCB, Eisai, Sanofi, GSK, and Jazz Pharmaceuticals. Competition in the market has been defined by the development of generic anticonvulsant drugs, increasing health insurance coverage, and innovations that address the unmet treatment needs of patients. While the local producers have been competing through generics and local marketing capabilities, foreign companies still have opportunities.

South Korea Antiepileptic Drugs Market Recent Developments News:

• In October 2026, Seoul Economic Daily reported that South Korea would introduce national health insurance coverage for XCOPRI (cenobamate), an innovative epilepsy drug developed by SK Biopharmaceuticals and commercialized domestically by Dong-A ST, effective November 1, 2026. Despite receiving U.S. FDA approval in 2019, the drug had initially been commercialized overseas, requiring South Korean patients to import it. The insurance coverage is expected to improve patient access by reducing treatment costs and import-related challenges, strengthening the domestic commercialization prospects of Korean-developed innovative epilepsy therapies. 

• In October 2026, ChosunBiz reported that South Korea's Ministry of Health and Welfare designated Samjin Pharmaceutical's lorazepam as a delisting-prevention drug to secure continued supply for pediatric seizure and epilepsy treatment. The designation followed supply disruptions after another domestic manufacturer discontinued production, prompting Samjin Pharmaceutical to take responsibility for manufacturing. Government coverage of production costs is intended to maintain the availability of essential, low-priced medicines that face limited commercial incentives for manufacturers. This development highlights the importance of government intervention in ensuring pharmaceutical supply continuity and maintaining access to established antiseizure treatments, particularly for pediatric patients. 

• In August 2026, Reuters reported that Biohaven entered into a licensing agreement with South Korea's SK Biopharmaceuticals worth up to US$795 million for Biohaven's epilepsy drug platform, including Opakalim. The agreement expands SK Biopharmaceuticals' access to investigational epilepsy therapies and strengthens its pipeline beyond internally developed products. This collaboration highlights growing international partnerships in antiseizure drug development and provides opportunities for Korean pharmaceutical companies to expand their innovative drug portfolios, strengthen research capabilities, and participate in the commercialization of next-generation epilepsy treatments.  

The South Korea Antiepileptic Drugs Market is dominated by a few large companies, such as

• Daewoong Bio

• Korea Pharma

• SK Biopharmaceuticals

• Bukwang Pharmaceutical

• Dong-Koo Bio & Pharma

• LG Chem

• Myungmoon Pharmaceutical

• Myungin Pharmaceutical

• Whanin Pharmaceutical

• Hanin Pharmaceutical

• Handok

• Dong-A ST

• Bukhwang Pharmaceutical

• Celltrion Pharm

• Hyundai Pharmaceutical

• Huons

• Myeongmun Pharmaceutical

• Korea United Pharm

• Daehan New Pharm

• Sam Chun Dang Pharm

• Other Prominent Players